Can we keep avoiding the simplest of all questions in a shifting medicines global order?

Australia has largely avoided serious consequences from PBS pricing because our market is comparatively small and has carried few global repercussions. In blunt terms, no one has really cared. Yet as the global context shifts and Australia’s pricing decisions attract greater attention, the question is now whether we have the maturity to engage in a serious discussion about how best to respond. …